推荐产品
应用
FTY720已被用作一种免疫调节剂，可用于研究其对P19C5干细胞的体外原肠胚模型的影响。它还可用于确定其延长角膜移植存活的功效。通过使用5-溴-2-脱氧尿苷掺入测定、神经球形成试验和蛋白质印迹分析，FTY720已被用于研究其对培养的胚胎海马神经干细胞（NSCs）的增殖和分化的影响。
生化/生理作用
FTY720是一种免疫调节药物以及1-磷酸鞘氨醇（S1P）受体的调节剂。 鞘氨醇激酶对FTY270的磷酸化可导致S1P1R的内化，从而螯合淋巴结中的淋巴细胞，阻止它们参与自身免疫反应。 临床上，它已被批准用于治疗多发性硬化症（MS）。研究显示其可通过抑制S1PR阻断和逆转紫杉醇诱导的化疗诱导的周围神经病变（CIPN），并可抑制小鼠脑海马中组蛋白脱乙酰酶的活性，从而调节记忆。
警示用语：
Warning
危险声明
预防措施声明
危险分类
STOT RE 2
靶器官
Immune system
WGK
WGK 3
闪点(°F)
Not applicable
闪点(°C)
Not applicable
M Mehling et al.
Neurology, 76(8 Suppl 3), S20-S27 (2011-02-26)
The oral sphingosine 1-phosphate (S1P) receptor (S1PR) modulator fingolimod has been shown to be effective in the treatment of patients with relapsing multiple sclerosis (MS). The drug binds with high affinity to 4 of the 5 G-protein-coupled S1P receptors (S1P(1-5)).
Goeril Karlsson et al.
Neurology, 82(8), 674-680 (2014-01-28)
To report outcomes of pregnancies that occurred during the fingolimod clinical development program. Pregnancy outcomes from phase II, phase III, and phase IV clinical studies (with optional extensions) were reported by clinical trial investigators. Fingolimod exposure in utero was defined
Paroxysmal atrial fibrillation after initiation of fingolimod for multiple sclerosis treatment.
Linda Rolf et al.
Neurology, 82(11), 1008-1009 (2014-02-14)
Fingolimod and teriflunomide attenuate neurodegeneration in mouse models of neuronal ceroid lipofuscinosis.
Groh J, et al.
Molecular Therapy, 25(8), 1889-1899 (2017)
M Kipp et al.
Multiple sclerosis (Houndmills, Basingstoke, England), 18(3), 258-263 (2012-03-03)
FTY720 (fingolimod; Gilenya®), a sphingosine 1-phosphate (S1P) receptor modulator, is the first oral disease-modifying therapy to be approved for the treatment of relapsing-remitting multiple sclerosis. FTY720 is rapidly converted in vivo to the active S-fingolimod-phosphate, which binds to S1P receptors.
商品
Discover Bioactive Small Molecules for Lipid Signaling Research
我们的科学家团队拥有各种研究领域经验，包括生命科学、材料科学、化学合成、色谱、分析及许多其他领域.
联系技术服务部门